ABRAXANE + CARBOPLATIN DELIVERED SIGNIFICANTLY SUPERIOR ORR VS PACLITAXEL

ABRAXANE + CARBOPLATIN DELIVERED SIGNIFICANTLY SUPERIOR ORR VS PACLITAXEL

ORR in the ITT population of the Phase III trial for first-line advanced or metastatic NSCLC
Overall response rate in the ITT population was 33% with ABRAXANE + carboplatin (n=170/521 [95% CI: 28.6%-36.7%]) vs 25% with paclitaxel injection + carboplatin (n=132/531 [95% CI: 21.2%-28.5%]) (P=0.005) - bar chart Overall response rate in the ITT population was 33% with ABRAXANE + carboplatin (n=170/521 [95% CI: 28.6%-36.7%]) vs 25% with paclitaxel injection + carboplatin (n=132/531 [95% CI: 21.2%-28.5%]) (P=0.005) - bar chart
  • P=0.005 (based on chi-square test).
  • Median duration of response was 6.9 months vs 6.0 months (95% CI: 5.6-8.0 vs 5.6-7.1, respectively)
  • No statistically significant difference in OS between the 2 study arms (median OS 12.1 months vs 11.2 months, P=NS10) ITT=intent-to-treat; NS=not significant.

41% ORR IN FIRST-LINE SQUAMOUS

41% ORR IN FIRST-LINE SQUAMOUS

Squamous advanced or metastatic NSCLC
RESPONSE RATE IN OTHER HISTOLOGIES

Carcinoma/Adenocarcinoma

  • 26% (66/254) for ABRAXANE + carboplatin vs 27% (71/264) for paclitaxel injection + carboplatin

Large cell carcinoma

  • 33% (3/9) for ABRAXANE + carboplatin vs 15% (2/13) for paclitaxel injection + carboplatin

Other forms of nonsquamous disease

  • 24% (7/29) for ABRAXANE + carboplatin vs 15% (5/33) for paclitaxel injection + carboplatin
YOU ARE NOW LEAVING www.abraxanepro.com
Additional Information for Readers Provided by Celgene Corporation

The clinical trial described in this article served as the
basis for the approval for ABRAXANE for Injectable Suspension.
The analyses contained in the article may differ from those in the package insert for ABRAXANE.

Please see Important Safety Information and Prescribing Information, including Boxed WARNING.

Click “OK” to proceed or “CANCEL” to return to
www.abraxanepro.com

OK
CANCEL